drugset / Trial / NCT04603937
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
RandomizedParallel-groupTriple-blindTreatment
Summary
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
Timeline
- Start
- 2020-09-30
- Primary completion
- 2023-04-27
- Completion
- 2023-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | Tarcocimab tedromer | Protein / enzyme biologic | 5 mg | Intravitreal |